title: Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation.
abstract: We demonstrate that Vgamma9gammadelta T cells activated by zoledronate can link innate and acquired immunity through crosstalk with dendritic cells (DCs) in a way that can amplify activation and proliferation of tumor antigen-specific CD8+ T cells. DCs pulsed with antigen alone or antigen plus zoledronate were used to stimulate the in vitro expansion of antigen-specific CD8+ T cells. MART-1-modified peptide (A27L peptide) and apoptotic HLA-A*0201-positive, MART-1-positive JCOCB tumor cell lines were used as tumor antigen sources. The percentage of A27L-specific CD8+ T cells within the responding lymphocytes on Day 7 when immature DCs (imDCs) were cultured in the presence of A27L peptide and 0.01 microM zoledronate was significantly higher (P=0.002, n=11) than that observed when imDCs were cultured with the lymphocytes in the presence of the A27L peptide alone. This enhancing effect of zoledronate was significantly reduced when gammadelta T cells were depleted from responding lymphocytes (P=0.030, n=5), indicating that the effect is mediated mainly through Vgamma9gammadelta T cells activated by zoledronate-pulsed imDCs. When imDCs copulsed with zoledronate and apoptotic JCOCB tumor cell lines were used, the percentage of A27L-specific CD8+ T cells was higher than that observed using imDCs with the apoptotic JCOCB lines alone, suggesting that zoledronate treatment of imDCs enhances the cross-presentation ability of DCs. These findings suggest a potentially valuable role for Vgamma9gammadelta T cell activation for expanding antigen-specific CD8+T cells using DCs copulsed with tumor antigen and zoledronate in the design of vaccine therapies for malignancy.
authors.affiliation: Medinet Medical Institute, Medinet Co. Ltd., 4-20-18 Seta, Setagaya-ku, Tokyo 158-0095, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Takahara
authors.forename: Manami
authors.initials: M
authors.lastname: Miyai
authors.forename: Mai
authors.initials: M
authors.lastname: Tomiyama
authors.forename: Masato
authors.initials: M
authors.lastname: Mutou
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Nicol
authors.forename: Mie
authors.initials: M
authors.lastname: Nieda
mesh_terms: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000276:immunology*; D050071:Bone Density Conservation Agents / Q000494:pharmacology; D016827:CD8 Antigens / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D018929:Cell Culture Techniques; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D004164:Diphosphonates / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology; D000077211:Zoledronic Acid
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D050071:Bone Density Conservation Agents; D016827:CD8 Antigens; D004164:Diphosphonates; D007093:Imidazoles; D016692:Receptors, Antigen, T-Cell, gamma-delta; D000077211:Zoledronic Acid